Review of clinical studies on combination therapy of 5a-reductase inhibitors and аі-blockers in patients with benign prostatic hyperplasia


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review presents the results of studies on combination therapy of 5a-reductase inhibitors and a1-blockers in patients with benign prostatic hyperplasia (BPH). These data demonstrate a significant advantage of the combination therapy versus monotherapy in terms of quality of life and subjective symptoms as well as the safety, better results in the prevention of BPH progression and acute urinary retention, and reduced need for surgery.

作者简介

L Spivak

Sechenov First Moscow State Medical University

Sechenov First Moscow State Medical University

K Lokshin

Lapino Clinical Hospital

Lapino Clinical Hospital

A Vinarov

Sechenov First Moscow State Medical University

Sechenov First Moscow State Medical University

参考

  1. Naslund M.J., Gilsenan A.W., Midkiff K.D., Bown A., Wolford E.T., Wang J. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int. J. Clin. Pract. 2007 ;61(9): 1437-1445.
  2. Wei J.T., Calhoun E., Jacobsen S.J. Urologic diseases in america project: benign prostatic hyperplasia. J. Urol. 2008; 179(5) :S75-80.
  3. Jacobsen S.J., Girman C.J., Lieber M.M. Natural history of prostatic hyperplasia. Urology. 2001;58(1):5-16.
  4. Jacobsen S.J., Jacobson D.J., Girman C.J. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. J. Urol. 1999;162:1301-1306.
  5. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A., Lieber M.M. Natural history of prostatism: Risk factors for acute urinary retention. J. Urol. 1997;158:481-487. 6.
  6. Roehrborn C, Fuh V., Ruane P, et al. The relationship between total and free PSA, prostate volume and age in men age 40-60 with no clinical diagnosis of benign prostatic hyperplasia necessitating therapy. J. Urol. 2000; 163:252A.
  7. Roehrborn C.G., Boyle P, Gould A.L. Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581-589.
  8. Roehrborn C.G., McConnell J.D., Lieber M.M., Kaplan S., Geller J., Malek G.H., Castellanos R., Coffield S., Saltzman B., Resnick M, Cook T.J., Waldstreicher J. Serum prostate specific antigen is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999;53:473-480.
  9. Epstein M., Oster J.R. Practical Management. Miami, Fla: Battersea, 1988.
  10. Пытель Ю.А. Медикаментозная терапия гиперплазии простаты. Пленум Всероссийского общества урологов. Саратов, 1994. С. 5-19.
  11. Marberger M. The MTOPS Study: New Findings, New Insights, and Clinical Implications for the Management of BPH. Eur. Urol. 2006;5(9):628-633. 12.
  12. EAU guidelines, 2015. https://uroweb.org/guideline/treatment-of-non- neurogenic-male-luts <https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts>.
  13. Roehrborn C.G., Siami P., Barkin J., Damiao R., Major-Walker K., Nandy I., Morrill B.B., Gagnier R.P., Montorsi F. on behalf of the CombAT Sudy Team. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from CombAT study. Eur. Urol. 2010;57:123-131. 14.
  14. Roehrborn, C.G., Oyarzabal Perez I., Roos E.P., Calomfirescu N., Brotherton B., Wang F., Palacios J.M., Vasylyev A., Manyak M.J. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with nitiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;7.
  15. Hutchison A., Farmer R., Verhamme K., Berges R., Navarrete R V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur. Urol. 2007;51:207-215.
  16. Erickson B.A., Lu X., Vaughan-Sarrazin M., Kreder K.J., Breyer B.N., Cram P. Initial treatment of men with newly diagnosed lower urinary tract dysfunction in the Veterans Health Administration. Urology. 2014; 83:304-309
  17. Kruep E.J., Hogue S.L., Eaddy M.T., Chandra M.D. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. P. T. 2011;36:493-507.
  18. Barkin J., Guimaraes M., Jacobi G., Pushkar D., Taylor S., van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur. Urol. 2003;44:461-466.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##